Publications by authors named "Lourdes Hernandez Gutierrez"
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study.
Javier García-Pérez María González-Pérez María Castillo de la Osa Alberto M Borobia Luis Castaño Lourdes Hernández-Gutierrez
EClinicalMedicine
August 2022
Article Synopsis
- The CombiVacS study examined the effectiveness and safety of combining two COVID-19 vaccines, ChAdOx1-S and BNT162b2, with initial results showing a robust immune response after 14 days.
- A secondary analysis tracked the immune response in 664 adults from the initial study up to 180 days, measuring both humoral (antibody levels) and cellular (T-cell response) immunity.
- By day 180, antibody levels declined significantly in both the intervention and control groups, indicating waning immunity over time, with notably lower responses to different COVID-19 variants.
Background: There is no evidence to date on immunogenic response among individuals who participated in clinical trials of COVID-19 experimental vaccines redirected to standard national vaccination regimens.
Methods: This multicentre, prospective controlled cohort study included subjects who received a COVID-19 experimental vaccine (CVnCoV)(test group, TG) - and unvaccinated subjects (control group, CG), selected among individuals to be vaccinated according to the Spanish vaccination program. All study subjects received BNT162b2 as a standard national vaccination schedule, except 8 (from CG) who received mRNA-1273 and were excluded from immunogenicity analyses.